September, 25, 2023 • Promising results of the PRECESTO clinical trial revealing a prolonged effect for NFL-101 and modification of the strategy for communicating the CESTO II study results

July, 18, 2023 • Patent application filed in the United States for reducing alcohol consumption with NFL-301 & preparation of a pre-IND application submission with the FDA

July, 05, 2023 • Co-founder shareholder further strengthens his position by exercising “BSPCE” warrants

June 29, 2023 • GB Holding takes a stake in the company’s capital upon the exercise of share subscription warrants and payment of 0.5m€, and also commits to a  lock-up

June 28, 2023 • Results of the combined general meeting of June 27, 2023

June 21, 2023 • Approval for its patent to be granted on NFL-101 in Europe and approval of the clinical development plan for NFL-101 by the EMA

May 09, 2023 • Recruitment completed for the PRECESTO study

April 25, 2023 • 2022 full-year business and earnings update

February 27, 2023 • Changes in the governance

February 22, 2023 • Inclusion of the first volunteer in the PRECESTO study

February 20, 2023 • NFL Biosciences receives €1.7 million in « Avance Innovation » funding from Bpifrance

February 02, 2023 • Collaboration with the CEA to study the mechanism of action of its drug candidate NFL-101

January 31, 2023 • Very successful capital increase for NFL Biosciences with over €3 million raised

January 30, 2023 • NFL Biosciences launches a round of fundraising for approximately 2.5 million euros

January 20, 2023 • CESTO II trial progressing on schedule

January 17, 2023 • Financial calendar for the first half of 2023

January 11, 2023 • NFL Biosciences receives a joint grant from the French Government and the Occitanie Region for its PRECESTO clinical trial

November 8, 2022 • Clinical trial approved to demonstrate the complementarity of NFL-101 with other smoking cessation treatments

November 2, 2022 • New patent application associating NFL-101 with other smoking cessation treatments

October 25, 2022 • 2022 first-half business and earnings

October 5, 2022 • NFL Biosciences partners with Themis Medicare for the development of NFL-101 in India

June 24, 2022 • NFL Biosciences to present at the H.C.Wainwright 1st annual mental health conference

May 25, 2022 • NFL Biosciences, committed to fight against smoking, fully supports World No Tobacco Day on May 31

May 11, 2022 • Decision to approve the issuing of its patent in South Korea

April 11, 2022 • Notice of allowance of its patent in China

March 28, 2022 • 2021 full-year business and earnings update

February 2, 2022 • Co-development agreement for a drug candidate to reduce alcohol consumption

December 14, 2021 • Phase II/III clinical trial launched for smoking cessation

November 17, 2021 • Agreement signed with Diverchim to manufacture its active ingredients

October 4, 2021 • 2021 half-year financial and business report

September 21, 2021 • Approval for its patent to be granted in the United States

September 15, 2021 • Phase II/III clinical trial for NFL-101 for smoking cessation approved in France

September 6, 2021 • Analyst coverage launched with Invest Securities

July 20, 2021 - Establishment of a liquidity agreement (in French only)

June 30, 2021 • Success of the IPO on Euronext Growth Paris

June 16, 2021 • NFL Biosciences launches its initial public offering on Euronext Growth Paris (in French only)

June 2, 2021 • French smoking cessation innovation approved for Phase II clinical trial (in French only)